VIEKIRA XR Drug Patent Profile

« Back to Dashboard

When do Viekira Xr patents expire, and what generic alternatives are available?

Viekira Xr is a drug marketed by Abbvie and is included in one NDA. There are eighteen patents protecting this drug.

The generic ingredient in VIEKIRA XR is dasabuvir sodium; ombitasvir; paritaprevir; ritonavir. There is one drug master file entry for this compound. Additional details are available on the dasabuvir sodium; ombitasvir; paritaprevir; ritonavir profile page.

DrugPatentWatch^® Generic Entry Outlook for Viekira Xr

Viekira Xr was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 13, 2032. This may change due to patent challenges or generic licensing.

There have been eighteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VIEKIRA XR

US Patents:	18
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	77
Drug Prices:	Drug price information for VIEKIRA XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIEKIRA XR
DailyMed Link:	VIEKIRA XR at DailyMed

See drug prices for VIEKIRA XR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VIEKIRA XR

Constraining patent/regulatory exclusivity:

8,691,938

NDA:

208624

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIEKIRA XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	Phase 4
Patient-Centered Outcomes Research Institute	Phase 4
Merck Sharp & Dohme Corp.	Phase 4

See all VIEKIRA XR clinical trials

US Patents and Regulatory Information for VIEKIRA XR

VIEKIRA XR is protected by eighteen US patents.

This potential generic entry date is based on patent 8,691,938.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	9,139,536
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	8,420,596		Y	Y
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	8,642,538		Y	Y

Expired US Patents for VIEKIRA XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016	7,148,359
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016	8,399,015
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016	8,268,349

International Patents for VIEKIRA XR

When does loss-of-exclusivity occur for VIEKIRA XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

France

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIEKIRA XR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3089757	FORMES GALÉNIQUES ANTIVIRALES SOLIDES (SOLID ANTIVIRAL DOSAGE FORMS)
Taiwan	201609195	Solid antiviral dosage forms
World Intellectual Property Organization (WIPO)	2015103490

Supplementary Protection Certificates for VIEKIRA XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203431	15C0013	France		PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
2340029	CA 2015 00013	Denmark		PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEROF; REG. NO/DATE: EU/1/14/982 20150115
2203431	CA 2015 00014	Denmark		PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115

VIEKIRA XR Market Dynamics and Financial Trajectory

Last updated: August 27, 2026

VIEKIRA XR was AbbVie’s once-daily, extended-release hepatitis C treatment for genotype 1 infection. Its commercial trajectory was short: strong initial demand for the VIEKIRA franchise in 2015-2016 was followed by rapid erosion from competing direct-acting antivirals, AbbVie’s own Mavyret launch, falling hepatitis C treatment volumes and market saturation. AbbVie withdrew VIEKIRA XR and VIEKIRA PAK from the U.S. market by the end of 2019. Product-specific VIEKIRA XR revenue was never publicly reported; AbbVie disclosed VIEKIRA franchise sales in aggregate.

What is VIEKIRA XR and what was its FDA status?

VIEKIRA XR is a fixed-dose extended-release tablet containing ombitasvir, paritaprevir, ritonavir and dasabuvir. It was approved by the FDA on July 25, 2016, for treatment of chronic hepatitis C virus infection caused by genotype 1 in adults. The product was administered once daily with food. Ribavirin was required for certain patient populations under the approved label. [1]

The product was a reformulation of VIEKIRA PAK, which required multiple tablets taken during the day. VIEKIRA XR was designed to simplify dosing and preserve the same core antiviral mechanism.

Product	Active ingredients	FDA approval	Primary indication	Commercial status
VIEKIRA PAK	Ombitasvir, paritaprevir, ritonavir, dasabuvir	December 2014	HCV genotype 1	Withdrawn from U.S. market
VIEKIRA XR	Same four active ingredients in extended-release formulation	July 25, 2016	HCV genotype 1	Withdrawn from U.S. market
Mavyret	Glecaprevir and pibrentasvir	August 2017	Broad HCV genotype coverage	Commercially active
Technivie	Ombitasvir, paritaprevir and ritonavir	July 2015	HCV genotype 4	Withdrawn from U.S. market

VIEKIRA XR was not a biologic. Biosimilar substitution was therefore not relevant. Competitive exposure came from small-molecule direct-acting antivirals, generic or authorized-generic entry and newer branded regimens.

How did VIEKIRA XR compare with VIEKIRA PAK?

VIEKIRA XR was primarily a dosing and formulation improvement rather than a new antiviral platform. The two products contained the same active antiviral components, but VIEKIRA XR consolidated the regimen into a once-daily extended-release tablet.

Attribute	VIEKIRA PAK	VIEKIRA XR
Dosing format	Multiple tablets, including morning and evening dosing	Once-daily extended-release tablets
Active ingredients	Four-drug regimen	Same four-drug regimen
Target population	Primarily genotype 1	Primarily genotype 1
Commercial objective	Initial VIEKIRA franchise product	Simplify administration and defend franchise
Main limitation	Complex dosing and drug interactions	Narrow genotype coverage and same core interaction burden
Market outcome	Declined rapidly after launch	Failed to establish a separate commercial revenue base

The reformulation arrived after the hepatitis C market had begun moving toward simpler, pan-genotypic regimens. VIEKIRA XR therefore had limited time to generate incremental value before Mavyret became AbbVie’s preferred HCV product.

What was VIEKIRA’s financial trajectory?

AbbVie did not report VIEKIRA XR sales separately. The available financial series covers VIEKIRA PAK and related VIEKIRA products, so the figures below should be interpreted as franchise revenue rather than VIEKIRA XR revenue alone.

Year	Approximate VIEKIRA franchise revenue	Market interpretation
2014	Initial launch period	VIEKIRA PAK entered the U.S. market late in the year
2015	Approximately $1.6 billion	Strong early uptake and high unmet demand
2016	Approximately $1.6 billion	High revenue but increasing competitive pressure
2017	Approximately $1.0 billion	Decline accelerated as HCV competition intensified
2018	Approximately $0.6 billion	Mavyret cannibalization and market contraction
2019	Below $0.2 billion	Late-stage decline before U.S. withdrawal

The figures reflect AbbVie’s annual reporting categories and may include VIEKIRA PAK, VIEKIRA XR and associated HCV products. They do not isolate VIEKIRA XR. [2-6]

Why did VIEKIRA revenue decline?

Four commercial forces drove the decline.

First, the HCV market rapidly shifted toward pan-genotypic regimens. Products such as Gilead’s Epclusa and AbbVie’s Mavyret treated broader patient populations with simpler dosing.

Second, VIEKIRA was restricted mainly to genotype 1 patients. As genotype testing and treatment expanded, physicians increasingly preferred regimens that covered multiple genotypes without requiring the same level of subtype-specific treatment selection.

Third, VIEKIRA had a relatively complex safety and drug-interaction profile. Ritonavir-mediated CYP3A inhibition created interaction-management requirements. The label also included warnings concerning hepatic decompensation and liver failure in susceptible patients. [1]

Fourth, AbbVie’s own Mavyret launch accelerated internal substitution. Mavyret offered an eight-week regimen for many treatment-naive patients without cirrhosis and carried broader genotype coverage. The product became the strategic successor to VIEKIRA in AbbVie’s HCV portfolio.

When did VIEKIRA XR lose market exclusivity?

VIEKIRA XR lost practical commercial exclusivity before the end of its expected patent life. The key loss was therapeutic and commercial, not necessarily a single patent expiration event.

The product’s effective exclusivity eroded through:

• Superior or broader branded alternatives.
• AbbVie’s launch of Mavyret.
• Declining HCV prevalence among untreated patients.
• Treatment completion by previously diagnosed patients.
• Pricing pressure from public and private payers.
• Generic and authorized-generic competition involving components or competing HCV regimens.

FDA approval in 2016 did not create a durable commercial moat because VIEKIRA XR was a reformulation of an existing combination. Its regulatory exclusivity position was weaker than that of a new molecular entity. The formulation could receive protection for the specific extended-release composition and manufacturing process, but those rights would not prevent physicians from switching to alternative antiviral combinations.

What patents protected VIEKIRA XR?

VIEKIRA XR was protected through a layered estate involving the active ingredients, fixed-dose combination, extended-release formulation, manufacturing processes and methods of treating HCV. The relevant rights were not limited to one product patent.

The principal patent categories were:

Patent category	Commercial purpose
Active-ingredient patents	Protect individual antiviral compounds
Combination patents	Cover use of the ombitasvir, paritaprevir, ritonavir and dasabuvir regimen
Formulation patents	Protect the extended-release tablet and release profile
Method-of-use patents	Cover treatment of HCV genotype 1 and related patient groups
Manufacturing patents	Protect compound synthesis, purification and tablet production

FDA Orange Book listings and USPTO records are the controlling sources for product-specific listed patents, expiration dates and pediatric extensions. The effective patent position depended on which claims applied to VIEKIRA XR rather than to the separate active ingredients or earlier VIEKIRA PAK product. [7-8]

Were there major Paragraph IV challenges?

VIEKIRA XR did not become the subject of a major, commercially consequential U.S. Paragraph IV generic launch comparable to litigation involving high-value single-product blockbusters. Its commercial decline was driven primarily by therapeutic substitution and AbbVie’s market transition to Mavyret.

Generic risk remained relevant because:

1. Individual active ingredients and competing HCV regimens could face separate challenges.
2. A generic product did not need to copy the entire VIEKIRA XR commercial strategy to pressure pricing.
3. Once AbbVie withdrew the product, the value of defending late-stage formulation or method claims diminished.

The absence of a prominent generic launch does not mean the patent estate was commercially decisive. By the time generic competition became a material consideration, the branded market had already shifted away from VIEKIRA XR.

What formulations were protected by VIEKIRA XR patents?

The main formulation distinction was the extended-release tablet. The formulation was intended to deliver the active components in a once-daily dosage form rather than reproduce the multi-tablet schedule associated with VIEKIRA PAK.

Potentially relevant formulation claim elements included:

• Extended-release matrices or coatings.
• Release timing for the individual active ingredients.
• Fixed-dose tablet composition.
• Stability of the four-drug combination.
• Food-dependent absorption characteristics.
• Manufacturing methods for maintaining dose uniformity.

Formulation protection had limited standalone commercial value because physicians could prescribe clinically effective alternative regimens without infringing the VIEKIRA XR formulation claims.

What was the competitive landscape for VIEKIRA XR?

VIEKIRA XR competed in one of the fastest-changing pharmaceutical markets of the decade.

Competitor	Company	Commercial advantage over VIEKIRA XR
Harvoni	Gilead Sciences	Simple once-daily regimen for major genotype 1 populations
Epclusa	Gilead Sciences	Pan-genotypic coverage
Zepatier	Merck	Alternative genotype 1 and genotype 4 option
Mavyret	AbbVie	Broad genotype coverage, shorter treatment courses and strong price positioning
Sovaldi-based regimens	Gilead Sciences	Established clinical use and broad treatment combinations

Mavyret was the most important competitor because it was also AbbVie’s replacement product. Its August 2017 approval allowed AbbVie to retain HCV revenue while moving customers away from the older VIEKIRA platform. [9]

The competitive comparison favored Mavyret on breadth and regimen simplicity:

Commercial factor	VIEKIRA XR	Mavyret
Genotype coverage	Primarily genotype 1	Pan-genotypic
Dosing complexity	Lower than VIEKIRA PAK but still clinically complex	Simpler
Treatment duration	Often longer or population-dependent	Frequently eight weeks in eligible patients
Drug-interaction burden	Significant due to ritonavir	Lower relative burden
Strategic role at AbbVie	Legacy HCV product	Core HCV franchise product

What regulatory and market events led to withdrawal?

The U.S. withdrawal reflected commercial obsolescence rather than a newly disclosed safety event that immediately invalidated the product. AbbVie had shifted its HCV strategy to Mavyret, while VIEKIRA demand fell sharply.

The relevant timeline was:

Date	Event
December 2014	FDA approved VIEKIRA PAK
July 2015	FDA approved Technivie
July 2016	FDA approved VIEKIRA XR
August 2017	FDA approved Mavyret
2017-2018	VIEKIRA sales declined as Mavyret and pan-genotypic therapies gained share
By end-2019	AbbVie withdrew VIEKIRA XR and VIEKIRA PAK from the U.S. market

The withdrawal reduced future revenue exposure but also ended the need to support a declining legacy formulation. Product discontinuation should be distinguished from FDA withdrawal for safety or efficacy reasons.

How strong was the VIEKIRA XR patent estate?

The patent estate was technically meaningful but commercially weakened by market substitution.

Strengths

• Multiple active pharmaceutical ingredients created several layers of intellectual property.
• Combination and method claims could support enforcement against direct copies.
• The extended-release formulation created a distinct product-specific layer.
• Manufacturing patents could increase the cost of designing around the product.

Weaknesses

• The product was limited mainly to genotype 1.
• The core antiviral components were shared with VIEKIRA PAK and were not a unique new molecular platform.
• Alternative HCV regimens avoided the formulation and combination claims.
• Mavyret provided AbbVie with a non-infringing internal replacement.
• The commercial market contracted before late-life patent enforcement became central.

Overall, the estate was stronger against a direct copy of VIEKIRA XR than against therapeutic substitution. Its principal commercial value was defensive rather than growth-oriented.

What generic launch scenarios existed for VIEKIRA XR?

Three launch scenarios were possible.

Direct generic substitution

A manufacturer could seek approval for a therapeutically equivalent version of the extended-release combination. This would have required overcoming product-specific formulation and combination patents, as well as demonstrating bioequivalence.

Component-based competition

Manufacturers could supply equivalent active ingredients or separate regimens without copying the VIEKIRA XR tablet. This route would pressure the product indirectly and avoid some formulation claims.

Therapeutic substitution

The most commercially important scenario involved switching patients to Mavyret, Epclusa, Harvoni or another approved direct-acting antiviral. This occurred before a direct VIEKIRA XR generic became a major market event.

What revenue exposure did VIEKIRA XR create for AbbVie?

VIEKIRA was material to AbbVie in its first full years but became immaterial relative to the company’s broader portfolio. The franchise generated approximately $1.6 billion annually at its peak, but the revenue base fell below $200 million by 2019 based on AbbVie’s reported VIEKIRA categories. [2-6]

The decline mattered because:

• HCV revenue was concentrated in a treatment class with high cure rates.
• Patients generally required one finite treatment course rather than chronic maintenance therapy.
• Payers had leverage over a curative but expensive treatment market.
• AbbVie’s own Mavyret launch shifted revenue within the HCV portfolio.
• The company’s financial exposure moved toward Humira, immunology, oncology and newer specialty products.

VIEKIRA XR itself likely represented only a minority of late-stage VIEKIRA revenue because it launched after VIEKIRA PAK had already established the franchise and was introduced when the market was entering structural decline.

Key Takeaways

• VIEKIRA XR was approved in July 2016 as a once-daily extended-release version of AbbVie’s VIEKIRA regimen.
• AbbVie did not disclose VIEKIRA XR revenue separately.
• Aggregate VIEKIRA franchise revenue peaked at roughly $1.6 billion in 2015-2016 and fell below $200 million by 2019.
• Mavyret was the principal commercial successor and internal competitor.
• VIEKIRA XR was disadvantaged by genotype 1 focus, drug-interaction concerns, treatment complexity and rapid adoption of pan-genotypic regimens.
• Its patent estate covered active ingredients, combinations, formulation, methods of use and manufacturing.
• Practical market exclusivity ended through therapeutic substitution before direct generic competition became decisive.
• AbbVie withdrew VIEKIRA XR and VIEKIRA PAK from the U.S. market by the end of 2019.
• Biosimilar risk was irrelevant because VIEKIRA XR was a small-molecule drug.
• Current commercial value is limited to historical revenue analysis, patent landscaping and HCV product-cycle studies.

FAQs About VIEKIRA XR

Is VIEKIRA XR still available in the United States?

No. AbbVie withdrew VIEKIRA XR from the U.S. market by the end of 2019.

Did VIEKIRA XR have separate sales from VIEKIRA PAK?

No separate public sales figure was reported. AbbVie disclosed VIEKIRA-related revenue in aggregate categories.

Was VIEKIRA XR replaced by Mavyret?

Yes. Mavyret became AbbVie’s primary HCV product after its FDA approval in August 2017.

Did VIEKIRA XR face biosimilar competition?

No. Biosimilar regulation applies to biologics. VIEKIRA XR was a chemically synthesized small-molecule combination.

Why was VIEKIRA XR commercially unsuccessful despite once-daily dosing?

Once-daily dosing improved convenience, but it did not solve the product’s narrow genotype coverage, interaction burden or exposure to newer pan-genotypic regimens.

References

1. U.S. Food and Drug Administration. (2016). Viekira XR prescribing information. FDA.

2. AbbVie Inc. (2015). 2015 annual report. AbbVie.

3. AbbVie Inc. (2016). 2016 annual report. AbbVie.

4. AbbVie Inc. (2017). 2017 annual report. AbbVie.

5. AbbVie Inc. (2018). 2018 annual report. AbbVie.

6. AbbVie Inc. (2019). 2019 annual report. AbbVie.

7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

8. United States Patent and Trademark Office. (2024). Patent Center and patent assignment records. USPTO.

9. U.S. Food and Drug Administration. (2017). Mavyret prescribing information. FDA.